-
A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans. But it’s unclear if it will will have support of the Trump administration.
-
Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the medications.
-
A neurologist, an internist and an infection control expert join the show to discuss what made news in the health care this past month.
-
In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a board member and former Shake Shack exec, was named interim chief.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.
-
But some health experts worry about traditional diet companies and gyms getting in the medication business and believe the drugs will cater to society’s need for quick fixes.
-
The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.
-
Health officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs, but they cannot definitively rule out “a small risk may exist."
-
Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.
-
Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.